Soluble betaglycan reduces renal damage progression in db/db mice

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 1, 2007, Pages

  Juárez, Patricia ^a   Vilchis Landeros, M Magdalena ^a   Ponce Coria, José ^a   Mendoza, Valentín ^a   Hernández Pando, Rogelio ^b   Bobadilla, Norma A ^b   López Casillas, Fernando ^a,c  

^a INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran ^*  (Mexico)

Author keywords

Collagen IV; Diabetic nephropathy; Fibronectin; Mesangial matrix expansion; Serum glucocorticoid kinase; Transforming growth factor

Indexed keywords

ALBUMIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CREATININE; FIBRONECTIN; GLUCOCORTICOID; GLYCAN DERIVATIVE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 33846187695     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00264.2006     Document Type: Article

References (36)

1. Arribas J, López-Casillas F, Massagué J. Role of the juxtamembrane domains of the transforming growth factor-α precursor and the β-amyloid precursor protein in regulated ectodomain shedding. J Biol Chem 272: 17160-17165, 1997.
2. Attisano L, Wrana JL, López-Casillas F, Massagué J. TGF-β receptors and actions. Biochim Biophys Acta 1222: 71-80, 1994.
3. Bandyopadhyay A, López-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62: 4690-4695, 2002.
4. Bandyopadhyay A, Wang L, López-Casillas F, Mendoza V, Yeh IT, Sun LZ. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 63: 81-90, 2005.
5. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. New Engl J Med 342: 1350-1358, 2000.
6. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslathi E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β. Nature 346: 371-374, 1990.
7. Breyer MD, Böttinger E, Brosius FC III, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
8. Cheifetz S, Hernandez H, Laiho M, Dijke P, Iwata KK, Massagué J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 265: 20533-20538, 1990.
9. Cohen MP, Lautenslager GT, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic db/db mice. Metabolism 50: 1435-1440, 2001.
10. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN. Prevention of diabetic nephropathy in db/db mice with glycanated albumin antagonists: a novel treatment strategy. J Clin Invest 95: 2338-2345, 1995.
11. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 37: 112-118, 2004.
12. Feliers D, Duraisamy S, Faulkner JL, Duch J, Lee AV, Abboud HE, Choudhury GG, Kasinath BS. Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int 60: 495-504, 2001.
13. Hernandez-Pando R, Orozco-Esteves H, Maldonado HA, Aguilar-Leon D, Vilchis-Landeros MM, Mata-Espinosa DA, Mendoza V, López-Casillas F. A combination of a transforming growth factor-β antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol 144: 264-272, 2006.
14. Hong SW, Isono M, Chen S, Iglesias-de la Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158: 1653-1663, 2001.
15. Kelly FJ, Anderson S, Thompson MM, Oyama TT, Kennefick TM, Coreless CL, Roman RJ, Kurtzberg L, Pratt BM, Ledbetter SR. Acute and chronic renal effects of recombinant human TGF-β2 in the rat. J Am Soc Nephrol 10: 1264-1273, 1999.
16. Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8: 133-146, 1994.
17. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447, 2000.
18. Lang F, Klingel K, Wagner CA, Stegen C, Wärntges S, Friedich B, Lanzendörfer M, Melzig J, Moschen I, Steuer S, Waldegger S, Sauter M, Paulmichl M, Gerke V, Risler T, Gamba G, Capasso G, Kandolf R, Helbert SC, Massry SC, Bröer S. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci USA 97: 8157-8162, 2000.
19. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-β2. Kidney Int 58: 2367-2376, 2000.
20. López-Casillas F, Payne HM, Andres JL, Massague J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and gag attachment sites. J Cell Biol 124: 557-568, 1994.
21. López-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 73: 1435-1444, 1993.
22. Massagué J. The transforming growth factor-β family. Annu Rev Cell Biol 6: 597-641, 1990.
23. Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
24. Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, Richards SM, Garman RD. Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 25: 235-257, 2003.
25. Sankar S, Mahooti-Brooks N, Centrella M, McCarthy J, Madri JA. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor β2. J Biol Chem 270: 13567-13572, 1995.
26. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kindey Int 69: 2131-2147, 2006.
27. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144, 2003.
28. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol Renal Fluid Electrolyte Physiol 266: F829-F842, 1994.
29. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu H. Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β type iii receptor-deficient embryos. Mol Cell Biol 23: 4371-4385, 2003.
30. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 290: F813-F820, 2006.
31. Velasco-Loyden G, Arribas J, López-Casillas F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 279: 7721-7733, 2004.
32. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernández G, López-Casillas F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-β neutralizing agent. Biochem J 355: 215-222, 2001.
33. Wang W, Koka V, Lan H. Transforming growth factor-β and Smad signaling in kidney diseases. Nephrology 10: 48-56, 2005.
34. Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW. Identification of distinct inhibin and transforming growth factor β-binding sites on betaglycan. Functional separation of betaglycan co-receptor actions. J Biol Chem 281: 17011-17022, 2006.
35. Yu L, Border WA, Huang Y, Noble NA. TGF-β isoforms in renal fibrogenesis. Kidney Int 64: 844-856, 2003.
36. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.